{
    "clinical_study": {
        "@rank": "119262", 
        "arm_group": {
            "arm_group_label": "Anakinra plus Standard of Care", 
            "arm_group_type": "Experimental", 
            "description": "Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity."
        }, 
        "brief_summary": {
            "textblock": "To determine the safety of administering anakinra plus the physician's chemotherapy choice\n      (TPC) of nab paclitaxel, capecitabine, eribulin, or vinorelbine in patients with metastatic\n      breast cancer (MBC), as well as determining blood immune cell transcriptional signatures in\n      patients who undergo IL-1 receptor blockade."
        }, 
        "brief_title": "Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "In an attempt to reverse the immune suppressive microenvironment and to enhance chemotherapy\n      effectiveness, decrease tumor metagenicity and decrease IL-1-induced fatigue, metastatic\n      breast cancer (MBC) patients will be treated with chemotherapy plus anakinra. This is a\n      pilot safety, single arm, open label trial. The objective is to determine the safety of\n      anakinra plus the physician's chemotherapy choice (TPC) of nab paclitaxel, capecitabine,\n      eribulin, or vinorelbine in patients with MBC and to define an anakinra-induced anti-IL-1\n      whole blood transcriptional profile."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female or male patients \u226518 years of age.\n\n          -  Histologically confirmed invasive breast cancer, locally unresectable or metastatic.\n\n          -  No more than 2 prior chemotherapy regimens for metastatic disease.\n\n          -  Patients currently being treated with nab paclitaxel, capecitabine,eribulin, or\n             vinorelbine who have had a CR, PR, or SD and who have developed Grade 2, 3, or 4\n             fatigue on the chemotherapy are eligible for the study. It should be anticipated that\n             these patients will continue to be treated on the same chemotherapy agent for at\n             least 3 more months beyond the time of enrollment.\n\n          -  Prior hormonal therapy in the adjuvant or metastatic setting is permitted.\n\n          -  HER2-negative breast cancer. If HER2-, it is defined as follows:\n\n               1. FISH-negative (FISH ratio <2.0), or\n\n               2. IHC 0-1+, or\n\n               3. IHC 2+ AND FISH-negative (FISH ratio<2.0)\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n\n          -  Adequate hematologic function, defined by:\n\n               1. Absolute neutrophil count (ANC) >1500/mm^3\n\n               2. Platelet count \u2265100,000/mm^3\n\n               3. Hemoglobin >8 g/dL\n\n          -  Adequate liver function, defined by:\n\n               1. AST and ALT \u22642.5 x the upper limit of normal (ULN) or \u22645 x ULN in presence of\n                  liver metastases\n\n               2. Total bilirubin \u22641.5 x ULN\n\n          -  Adequate renal function, defined by:\n\n             a. Serum creatinine \u22641.5 x ULN or calculated creatinine clearance of \u226540 ml/min\n\n          -  Measurable or nonmeasurable disease by RECIST v1.1 criteria\n\n          -  Life expectancy \u226524 weeks\n\n          -  Adequate recovery from recent surgery\n\n               1. Major surgical procedure >28 days from study entry\n\n               2. Minor surgical procedure >7 days from study entry (Portacath placement accepted\n                  - patients can start treatment <7 days after portacath placement.)\n\n          -  Patients with previous history of invasive cancers (including breast cancer) are\n             eligible if definitive treatment was completed more than 5 years prior to initiating\n             current study treatment, and there is no evidence of recurrent disease.\n\n          -  Patient must be accessible for treatment and follow-up.\n\n          -  All patients must be able to understand the investigational nature of the study and\n             give written informed consent prior to study entry\n\n        Exclusion Criteria:\n\n          -  Patients with active or untreated brain metastases or meningeal metastases are\n             ineligible. Patients who have had brain metastases resected, or have received brain\n             radiation therapy >4 weeks prior to study entry are eligible if they meet all of the\n             following criteria: 1) patient has been off dexamethasone for >2 weeks; 2) no known\n             progression of brain metastasis.\n\n          -  Previous radiotherapy for metastatic disease completed <2 weeks prior to study\n             treatment initiation.\n\n          -  Women who are pregnant or lactating. All patients with reproductive potential must\n             agree to use effective contraception from time of study entry until at least 3 months\n             after the last administration of study drug.\n\n          -  Patients who have any severe and/or uncontrolled medical conditions or other\n             conditions that could affect their participation such as:   -\n\n               1. severe impaired lung functions as defined as spirometry and DLCO that is 50% of\n                  the normal predicted value and/or O2 saturation that is 88% or less at rest on\n                  room air\n\n               2. uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN\n\n               3. liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class\n                  C).\n\n          -  History of any other disease, physical examination finding, or clinical laboratory\n             finding giving reasonable suspicion of a disease or condition that contraindicates\n             use of an investigational drug, or that might affect interpretation of the results of\n             this study, or render the subject at high risk for treatment complications.\n\n          -  Patients may not receive any other investigational treatments while participating in\n             this study.\n\n          -  Patients receiving chronic, systemic treatment with corticosteroids or another\n             immunosuppressive agent. Topical or inhaled corticosteroids are allowed.\n\n          -  Concurrent severe, uncontrolled infection or intercurrent illness including, but not\n             limited to, ongoing or active infection, or psychiatric illness/social situations\n             that would limit compliance with study requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802970", 
            "org_study_id": "012-099"
        }, 
        "intervention": {
            "arm_group_label": "Anakinra plus Standard of Care", 
            "description": "Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.", 
            "intervention_name": "Anakinra plus Standard of Care", 
            "intervention_type": "Drug", 
            "other_name": [
                "Anakinra: kineret", 
                "Nab paclitaxel: Abraxane", 
                "Capecitabine: Xeloda", 
                "Eribulin: Halaven", 
                "Vinorelbine: Navelbine"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vinorelbine", 
                "Paclitaxel", 
                "Capecitabine", 
                "Interleukin 1 Receptor Antagonist Protein"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Anakinra", 
            "Nab Paclitaxel", 
            "Capecitabine", 
            "Eribulin", 
            "Vinorelbin"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "grace.townsend@baylorhealth.edu", 
                "last_name": "Grace Townsend", 
                "phone": "214-818-8382"
            }, 
            "contact_backup": {
                "email": "silviya.meletath@baylorhealth.edu", 
                "last_name": "Silviya Meletath", 
                "phone": "214-820-4987"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75246"
                }, 
                "name": "Baylor University Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Joyce O'Shaughnessy, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Karolina Palucka, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients", 
        "overall_contact": {
            "email": "grace.townsend@baylorhealth.edu", 
            "last_name": "Grace Townsend", 
            "phone": "214-818-8382"
        }, 
        "overall_contact_backup": {
            "email": "silviya.meletath@baylorhealth.edu", 
            "last_name": "Silviya Meletath", 
            "phone": "214-820-4987"
        }, 
        "overall_official": {
            "affiliation": "Baylor Health Care System", 
            "last_name": "Joyce O'Shaughnessy, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will receive anakinra plus the physicians chemotherapy choice of nab paclitaxel, or capecitabine, or eribulin, or vinorelbine for metastatic breast cancer. Adverse events will be recorded throughout the trial, and regardless of the severity will be followed up by investigator until resolution is satisfactory. All adverse events and toxicities will be recorded and assessed for 30 days following the last dose of anakinra at a maximum of 6 months. Grading will be done using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.", 
            "measure": "Safety - Adverse Events in participants", 
            "safety_issue": "Yes", 
            "time_frame": "up to 7 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802970"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Objective response rate, clinical benefit rate and progression-free survival in patients will be determined using radiological assessment of tumors (CT/MRI/X-ray/PET), clinical and functional evaluation of patients with 95% confidence intervals. Whole blood transcriptional profiling will be performed to determine a gene expression signature that is induced by IL-1 receptor blockade by anakinra. The gene expression signatures from baseline will be compared to those signatures obtained after the 2-week run-in treatment with anakinra alone. During the treatment, complete blood count with differential/platelet count and complete metabolic profiling will be done to identify any baseline changes.", 
            "measure": "To determine investigator-assessed objective response rate, clinical benefit rate, progression-free survival, and rates of chemotherapy or cancer-related anemia (HgB<10), and an anakinra-induced anti-IL-1 blood transcriptional signatures", 
            "safety_issue": "No", 
            "time_frame": "upto 7 months"
        }, 
        "source": "Baylor Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baylor Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}